Pyoderma Gangrenosum Associated with Crohn Disease: Effect of TNF- α Blockade with Infliximab |
| |
| Authors: | T Ljung M Staun O Grove O Fausa M H Vatn P M Hellström |
| |
| Institution: | 1. Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, and Baylor College of Medicine, Houston, Texas, USA;2. Department of Oncology and Neuroscience, Section of Molecular Pathology, University “G. d'Annunzio”, and Center of Excellence on Aging, “G. d'Annunzio” Foundation, Chieti, Italy;3. CBLPath, Inc, Rye Brook, New York;4. New York University School of Medicine, North Shore University Hospital-Long Island Jewish System, New York, USA |
| |
| Abstract: | Eight patients with pyoderma gangrenosum associated with Crohn disease were treated with infliximab. All had active mucosal inflammation indicated by endoscopic examination. Within 1-4 months, infliximab treatment resulted in complete healing of the pyoderma gangrenosum in 3 cases (1 parastomal, 2 lower limb), partial healing in 3 (2 parastomal, 1 lower limb) and temporary improvement in 2. Adverse effects such as skin rash, pneumonia and diarrhoea were seen in three patients. Our results imply that infliximab has a therapeutic potential on skin manifestations associated with inflammatory bowel disease, even though successful treatment may require repeat courses of infliximab infusions. |
| |
| Keywords: | Cytokines Extra-INTESTINAL Inflammatory Bowel Disease Skin Lesion |
|
|
